The Centers for Disease Control and Prevention released new research showing high adherence to daily oral pre-exposure prophylaxis, or PrEP, for HIV prevention among heterosexual men and women in Botswana. The data come from a 12-month open-label extension of the study known as TDF2. Key findings include:
- Both men and women were highly adherent to daily PrEP throughout the study period
- There were no HIV infections among study participants
- There was no increase in sexual risk behavior – in fact, sexual risk behavior among participants declined over the course of the study
Because an open-label extension more closely replicates a real-world setting than the preceding clinical trial, the findings may provide a better indication of likely PrEP adherence and effectiveness outside of a research setting.
The findings also underscore the important role of PrEP in protecting the health of women. In the wake of PrEP trials in which women have experienced no protection against HIV because they were not taking the medication as prescribed, the study offers reassurance that at-risk women who seek PrEP can adhere to a daily regimen.
The findings were presented at the 2015 International AIDS Society Conference in Vancouver, Canada.